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Early afterdepolarisation tendency as a simulated
pro-arrhythmic risk indicator†
Beth McMillan, *a David J. Gavaghan a and Gary R. Mirams b
Drug-induced Torsades de Pointes (TdP) arrhythmia is of major interest in predictive toxicology. Drugs
which cause TdP block the hERG cardiac potassium channel. However, not all drugs that block hERG
cause TdP. As such, further understanding of the mechanistic route to TdP is needed. Early afterdepolari-
sations (EADs) are a cell-level phenomenon in which the membrane of a cardiac cell depolarises a second
time before repolarisation, and EADs are seen in hearts during TdP. Therefore, we propose a method of
predicting TdP using induced EADs combined with multiple ion channel block in simulations using bio-
physically-based mathematical models of human ventricular cell electrophysiology. EADs were induced in
cardiac action potential models using interventions based on diseases that are known to cause EADs,
including: increasing the conduction of the L-type calcium channel, decreasing the conduction of the
hERG channel, and shifting the inactivation curve of the fast sodium channel. The threshold of interven-
tion that was required to cause an EAD was used to classify drugs into clinical risk categories. The metric
that used L-type calcium induced EADs was the most accurate of the EAD metrics at classifying drugs
into the correct risk categories, and increased in accuracy when combined with action potential duration
measurements. The EAD metrics were all more accurate than hERG block alone, but not as predictive as
simpler measures such as simulated action potential duration. This may be because diﬀerent routes to
EADs represent risk well for diﬀerent patient subgroups, something that is diﬃcult to assess at present.
Introduction
Torsades de Pointes (TdP) is a particular type of polymorphic
ventricular tachycardia, characterised by an unusual electro-
cardiogram, in which the QRS complex appears to be twisted
around the baseline. TdP usually spontaneously resolves,
sometimes causing syncope (sudden fainting due to a drop in
blood pressure), but it can also cause cardiac arrest or sudden
death.1,2
Anti-arrhythmic drugs, such as quinidine,3 are commonly
linked to TdP. Terfenadine, a non-sedating anti-histamine, was
one of the first non-cardiac drugs to be linked to increased
TdP risk.4 Terfenadine was withdrawn from the market in 1997
after being linked to 41 cases of TdP, one of which was lethal.5
Cisapride is a drug that was used for treating gastroesophageal
reflux disease.6 After causing 97 cases of TdP, of which six
were fatal, cisapride was withdrawn from the market.7
Quinidine, terfenadine, and cisapride were all found to
strongly block IKr, the rapid delayed rectifying potassium
current in the heart, which is carried by the channel whose
primary subunit is a product of the human ether-a-go-go
related gene (hERG).4,6,8,9
Since these discoveries, testing for hERG block has become
a mandatory requirement for new pharmaceuticals.10 hERG
block as a measure of TdP risk is very sensitive (gives few false
negatives) and has prevented torsadogenic drugs from enter-
ing the market. Certain marketed drugs, such as verapamil
and ranolazine, block hERG but are not linked with TdP.11,12
There are therefore concerns that hERG block lacks specificity
(gives false positives for TdP risk), preventing the development
of potentially useful drugs.13 As such, elucidation of other
factors that mediate TdP risk is needed.
Early afterdepolarisations (EADs), phenomena in which the
membrane depolarises a second time during the action poten-
tial, are heavily implicated in the onset of TdP.15 Hearts
suﬀering from TdP show EADs alongside transmural dis-
persion of repolarisation.16–19 EADs are seen in monophasic
action potential recordings from dog hearts during TdP, as
shown in Fig. 1.14,19
Our investigation is based on several mechanisms that are
known to promote EADs. One mechanism is based on a form
of Long QT syndrome (LQT8) that is caused by an increase in
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the L-type calcium current, caused by a gain of function
mutation in the CACNA1C gene, that increases the density of
L-type calcium channels at the cell surface up to three-
fold.20,21 Patients with LQT8 frequently exhibit TdP.22 L-type
calcium current agonists (agents which increase the conduc-
tance of the L-type calcium channel) have also been shown to
cause: TdP in live mice;23 EADs and ventricular tachycardia in
intact mouse hearts;24 EADs in sheep and dog Purkinje
fibres;25 and EADs in ferret ventricular myocytes.26 L-type
calcium current blockers such as verapamil are used as anti-
arrhythmic agents, and have been shown to suppress EADs
and TdP in rabbit models of LQT3 and chronic heart
failure.11,27,28
Another EAD mechanism we investigate in this study is
based on Brugada syndrome, which is a condition linked to
ventricular fibrillation and elevation in the ST segment of the
electrocardiogram.29 Estimates of the proportion of sudden
deaths caused by Brugada vary from 4–12%, and it is estimated
to be present in 0.05% of the world population. In 15–20% of
Brugada cases, the cause is a mutation in the SCN5A gene,
which codes for the alpha subunit of the fast sodium
channel.29 A missense mutant version of SCN5A (T1620M),
was shown to alter the inactivation curve of the fast sodium
current, shifting it in the positive direction by 10 mV,30 and
another missense mutant, L812Q, shifted the inactivation
curve by 20 mV.31 Adding this inactivation curve shift to
cardiac action potential models can cause EADs (Noble et al.,
personal communication).
In addition to being of interest in drug-induced TdP, the IKr
potassium current is also involved in LQT2, and is also linked
to EADs.9 Loss-of-function mutations in hERG cause a
reduction in the IKr current of up to 97%,
32 which causes QT
prolongation, and usually increases risk of TdP. LQT
mutations do not always present with significant clinical QT
prolongation, but interaction with drugs that aﬀect cardiac ion
channels could cause an increased risk of TdP.33
Two other Long QT conditions that are linked to TdP are
LQT1 and LQT3.34 LQT1 causes an increase in the slow
delayed potassium current IKs, and LQT3 causes an increase in
the persistent sodium current IpNa. We have not used these as
EAD-provoking interventions in this work because we were
unable to provoke EADs in the O’Hara cell model by blocking
IKs or increasing IpNa.
The prediction of arrhythmias by in silico modelling of
action potentials in response to ion channel block oﬀers a new
way to test novel compounds at the pre-clinical stage. A pre-
vious study by our group created an improved measure of a
compound’s propensity for causing TdP arrhythmias, using
simulated action potential duration as a metric.35 The
approach takes into account the contributions of multiple ion
channels to the shape and length of the action potential, and
classifies drugs into discrete risk categories, based on their
eﬀect on action potential duration. This method was more
accurate than the commonly-used ‘hERG safety factor’, that is
the ratio of hERG IC50 to eﬀective free therapeutic plasma con-
centration (EFTPC), or log10(hERG IC50/EFTPCmax).
36
Simulation studies have been extended to predict results of
rabbit wedge studies and the Thorough QT study.37,38
A recent study used principal component analysis to assem-
ble a large number of biomarkers from diﬀerent models, the
results suggested that a two-dimensional binary classification
based on both the simulated diastolic calcium concentration
and the APD50 was eﬀective at separating drugs into positive
or negative for torsadogenicity.39 We aim to extend these
approaches to allow prediction of the TdP risk classes of drugs
that increase action potential duration but are safe (particu-
larly late/persistent sodium blockers), and to account for the
interaction of drug block with underlying conditions such as
ion channel mutations. The appearance of EADs at increased
drug concentrations has been studied computationally as a
risk indicator for TdP.40 Our study complements this work by
exploring EADs as a risk indicator in the context of disease
states at clinically-relevant concentrations.
Ion channel conductance modification as a cause of EADs
has also been investigated recently in the context of atrial
fibrillation: a global sensitivity analysis of atrial cell models
was used to examine which ion channel changes lead to EADs
and then logistic regression was used to estimate the prob-
ability of EADs as functions of conductances.41
The Comprehensive in vitro Pro-arrhythmia Assay (CiPA) is
a proposal to use multi-ion channel screening in combination
with human stem cell-derived cardiomyocytes and compu-
tational cardiac modelling to create new metrics for the predic-
tion of drug-induced TdP, moving away from using QT interval
prolongation as a surrogate marker and towards in vitro and
in silico methods.42 This study investigates whether a marker
linked mechanistically to EAD formation may be helpful in
determining torsadogenic risk.
We applied ion channel block to cardiac cell models to
simulate the eﬀects of drugs of known torsadogenic risk, then
combined these drug eﬀects with simulated disease states.
The level of disease state necessary to provoke an EAD for each
drug was used as a marker for TdP risk. These markers were
evaluated against clinical risk categories, separately, com-
Fig. 1 Induction of EADs and TdP in an anaesthetised dog by treatment
with ibutilide.14 Reproduced with permission from P. G. A. Volders, et al.,
Progress in the understanding of cardiac early after depolarizations and
torsades de pointes: time to revise current concepts, Cardiovasc. Res.,
2000, 46(3), 376–392. Published by Oxford University Press on behalf of
the European Society of Cardiology (ESC).
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bined, and in combination with pre-existing TdP risk metrics.
By combining these markers we hope to create a measure of
risk for a population that contains people with each EAD-indu-
cing condition. In this way, we bring together three key factors
that influence arrhythmogenic risk: the ion channel blocking
properties of the compounds, the concentrations of compound
found in humans, and underlying risk factors from the
patient.
Methods
We selected 41 drugs of known torsadogenic risk, and simu-
lated their ion channel blocking eﬀects in the O’Hara
2011 human ventricular cell model.43 Using a range of inter-
ventions, we determined the threshold of intervention at
which an EAD could be provoked in the cell model, i.e. the
lowest level of intervention that was necessary for an EAD to be
produced. The diﬀerences in ‘threshold for EAD’ between
diﬀerent drugs were used to classify drugs by arrhythmic risk.
These steps are detailed below.
Drug inclusion criteria
To select drugs to use as a training set, we used three criteria
based on the amount of data available on both the pro-arrhyth-
mic risk of the compound and its eﬀect on ion currents in
cardiac cells.
1. As a starting point, we included drugs that we previously
studied in Mirams et al.35
2. Additional drugs were then included in our study if they
had been included in five or more of the papers analysing TdP
risk discussed in a recent summary paper,44 and if over 70% of
studies agreed on high or low TdP risk.
3. Drugs that are on the CiPA list42 were automatically
included if ion current block data were available for three or
more channels of interest (even if they had been in fewer than
five studies or had poor agreement in risk category between
studies).
If there was disagreement in risk class using the above
sources, the default category was the one used in Mirams
et al.,35 and if not listed there then the one used in Redfern
et al.36
To be included in our dataset, the drugs were also required
to have IC50 values available in the literature for three or more
of the ionic currents of interest, found by manual patch
clamp. The ionic currents of interest were: the fast and late/
persistent sodium currents, the L-type calcium current, the
rapid and slow delayed rectifier potassium currents, the transi-
ent outward current, and the inward rectifier potassium
current. The pIC50 values we used are given in Table 1, and the
references for these can be found in the ESI.† Where there
were multiple IC50 values available, preference was given to
those from human cells at body temperature (37 °C) and to the
most recent study.
Stratification into 4 risk categories was taken from the
Mirams et al. (2011) paper where available, and the Redfern
et al. (2003) paper otherwise. We pooled risk categories 1 and 2
together, as they represent the same risk level for diﬀerent
drug classes, leaving classes 2–5.35,36 The only compounds in
the dataset not covered by this metric were: (i) ranolazine,
which was assigned to category 4, i.e. the drug has isolated
reports of TdP in humans; and (ii) cibenzoline, which was
assigned to category 5 based on Lawrence et al.,45 i.e. there are
no reports of TdP in humans with this drug.46,47
Action potential and drug block models
We used two recent human ventricular myocyte electrophysi-
ology models based on human datasets, the O’Hara (2011)43
endocardial and Grandi (2010)49 models. Drug block of ion
channels was modelled as a reduction in channel conductance
as a function of the concentration of the compound, [D], and
the IC50 value.
50 The change in maximum conductance for a
channel j was described by a Hill equation:
gj ¼ gˉ j 1þ
½D
½IC50
  1
; ð1Þ
where gj is the maximum conductance of the drug-blocked
channel, and gˉj is the conductance of the channel when there
is no compound present. The Hill coeﬃcient here is set to 1,
as the variability in experimentally-inferred Hill coeﬃcients
from patch clamp can be so high that using 1 as the Hill coeﬃ-
cient may reduce error.51 Note that this formula was applied
for all channel/drug combinations listed in Table 1, apart from
late/persistent sodium in the Grandi model—as this model
does not have a distinct late/persistent sodium current.
Drug concentrations were set to the maximum eﬀective free
therapeutic plasma concentrations (EFTPC) for each individual
drug, to provide a realistic estimate of ion channel block
in vivo. For a list of EFTPCs, see Table 1.
Detecting afterdepolarisations
The appearance of early afterdepolarisations (EADs) in a simu-
lation was determined by the slope of the voltage trace
between adjacent time points. Whenever the slope was greater
than +1 mV ms−1, a depolarisation was reported. To remove
depolarisations caused by the stimulus, depolarisations that
occurred between 50 ms before and 100 ms after each stimulus
were disregarded. The algorithm detects single EADs, multiple
EADs, and EADs without repolarisation, as shown in Fig. 2.
For the full algorithm, see the DetectAfterDepolarisations class
in the code repository (see “Numerical methods and simu-
lation procedure”).
Provoking afterdepolarisations
The failure of hERG block alone to predict torsadogenic risk
suggests that drug-induced TdP is mediated by more than one
ionic mechanism. We hypothesise that the interaction of
certain disease states with torsadogenic drugs could lead to
greater susceptibility to TdP. We propose to look at the single-
cell phenomenon of EADs, as studies suggest TdP and EADs
are intrinsically linked.14,16–19 Spatial diﬀerences in ion
Paper Toxicology Research
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channel expression throughout cardiac tissue would alter the
susceptibility of each cell to EADs, meaning that some regions
would have EADs while others did not, increasing the prob-
ability of re-entrant waves, but we constrain this study to
looking at the ‘trigger’ event of EAD initiation.
To simulate disease states after drug block was applied,
EADs were provoked using three interventions mimicking
disease states discussed in the introduction, based on a manu-
script from Noble et al.:52
• conductance of the L-type calcium current was increased
by a scaling factor to simulate a gain-of-function mutation
which causes LQT8.21
• the midpoint of the inactivation curve of the fast sodium
current was shifted using an additive constant to simulate
Brugada syndrome.30
• conductance of the rapid delayed rectifier current IKr was
decreased by a scaling factor to simulate the eﬀect of
LQT2 mutations.9
Table 1 pIC50 values for each compound in the dataset (shown as logM) for the fast sodium (INa), L-type calcium (ICaL), rapid delayed rectiﬁer pot-
assium (hERG or IKr), slow delayed rectiﬁer potassium (IKs), persistent sodium (IpNa), transient outward (Ito) and inward rectiﬁer potassium (IK1) cur-
rents, and eﬀective free therapeutic plasma concentration (EFTPC) (nM). For references, please see the ESI. ‘n/a’ indicates that the channel has been
screened and no eﬀect was measured: either the IC50 value was above the maximum concentration being tested, or there is no drug-induced block
of this channel
Compound
pIC50 (logM)
EFTPCmax (nM)INa ICaL hERG IKs IpNa Ito IK1
Ajmaline 5.0862 4.1487 5.9830 5.5751 17 103
Amiodarone 4.3936 6.5686 7.5229 5.7595 5.1739 5.4250 0.5
Amitriptyline 4.6990 4.9355 5.4841 5.5627 5.3533 5.0000 41
Azimilide 4.7212 4.7496 7.0000 5.8539 70
Bepridil 5.4318 6.6757 6.2218 5.0000 5.7414 5.1805 33
Chlorpromazine 5.5528 5.5229 5.8297 5.3410 4.7959 5.2147 38
Cibenzoline 5.1079 4.5229 4.6459 4.9101 4.3318 976
Cisapride 4.8327 4.7959 8.1871 5.4698 5.0301 4.9
Clozapine 5.6021 1603
Desipramine 5.8182 5.7673 5.8570 108
Diltiazem 4.8477 7.2676 5.1314 4.5346 122
Disopyramide 5.7447 4.0910 4.6799 742
DL-Sotalol 3.5560 14 733
Dofetilide 3.5229 4.5735 8.3010 2
Flecainide 5.1871 4.5918 5.7959 5.4685 5.1079 753
Fluvoxamine 4.4045 5.3098 5.4202 264
Halofantrine 7.6655 0.5
Imipramine 5.4437 5.0915 5.4685 4.3010 106
Loratadine 5.0809 0.45
Methadone 4.9508 4.5735 5.3188 507
Mexiletine 4.3665 4.0000 4.3010 4.7545 4129
Mibefradil 6.0088 6.8069 5.7447 5.4403 12
Nifedipine 4.4318 7.2218 3.5607 3.4437 4.8633 7.7
Nitrendipine 4.6655 7.6021 5.0000 5.1135 3.02
Ondansetron 4.0531 4.6468 6.0915 4.7171 899.88
Pentamidine 3.6882 6.7696 10
Phenytoin 4.3098 3.9872 4.0000 7000
Pimozide 7.2676 6.6198 7.8239 0.43
Prenylamine 5.5986 5.9066 7.1871 17
Propafenone 5.9245 5.7447 6.3565 5.3940 5.3188 5.1487 241
Propranolol 5.6778 4.7447 5.5485 26
Quetiapine 4.7721 4.9830 5.2392 33
Quinidine 4.7799 4.8069 6.5229 5.3099 3.0580 3.6990 3237
Ranolazine 3.5317 3.5287 4.9393 2.7212 5.1871 3200
Risperidone 3.9914 4.1367 6.2218 1.81
Sertindole 5.6383 5.0506 7.8539 6.0555 5.3979 1.59
Tedisamil 4.6990 5.6021 5.3565 85
Terfenadine 6.0128 6.4260 8.0506 5.6990 9
Terodiline 4.8182 8.3979 4.5229 5.1549 12
Thioridazine 5.7375 5.8861 7.4815 4.8539 979
Verapamil 4.3820 7.0000 6.8447 2.5796 81
Fig. 2 Types of EADs that are detected using the EAD detection algor-
ithm. Left: A single EAD with repolarisation. Centre: Multiple EADs with
repolarisation. Right: Multiple EADs without repolarisation.
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The O’Hara et al.43 model was used for these EAD simu-
lations, as it includes all of the currents of interest, and is
being investigated for CiPA-related proarrythmic risk
prediction.42
We used a slow pacing interval of 3 seconds because brady-
cardia is also known to facilitate onset of EADs and TdP.17 We
performed the same simulations at faster pacing rates, which
did not significantly change the classification results.
Previously suggested measures
In order to compare our EAD tendency measures with pre-
viously suggested risk indicators, we used our dataset of drug
actions to calculate some risk metrics that have previously
been proposed.
We calculated the hERG IC50/EFTPCmax safety margin pro-
posed by Redfern et al.;36 the predicted APD90 calculated using
the Grandi et al.49 human ventricular cell model, as in Mirams
et al.;35 the predicted APD50 combined with diastolic calcium
concentration calculated using both the Grandi et al.49
model, and the O’Hara et al.43 model as in Lancaster and
Sobie;39 and the predicted sum of normalised total persistent
sodium current and L-type calcium current over the course of
the action potential at increasing drug concentrations (known
as ‘cqInward’) using the O’Hara et al.43 model, as in Li et al.,48
but using the baseline model rather than their dynamic hERG
block model (as we did not have hERG kinetic data for all com-
pounds). The Grandi model was chosen for APD90 rather than
the O’Hara model as it was used in the Mirams et al. (2011)
metric.
Numerical methods and simulation procedure
Simulations were run using the Chaste C++ framework53,54
with the ApPredict bolt-on project55 and custom written code.
Cell models and initial conditions were imported from
CellML56 files using PyCML.57
The adaptive timestep solver CVODE58 was used to solve the
model’s diﬀerential equations, with a relative tolerance of 10−5
and absolute tolerance of 10−7. The output timestep was
0.1 ms and a stimulus current was applied every 3 s for 3 ms
with a magnitude of −25.5 μA μF−1.
The procedure we used is outlined in Algorithm 1. First,
drug block was applied to the model by modifying the conduc-
tance parameters for the appropriate channels, using eqn (1)
to calculate updated conductances. The model was then run to
steady state using the pacing protocol above. Steady state was
reached when the norm of the change in the model’s state
variables was less than 10−6 between paces. This generally
took 1000–10 000 paces.
EAD-provoking interventions were applied by modifying
either the ICaL conductance, the IKr conductance, or the INa
shift parameter. After setting the intervention parameter, the
simulation was run for 12 s, and the presence or absence of
EADs was detected. Interval bisection was used to find the
threshold of intervention that was necessary to cause any
EADs. We started with interval ranges of: [0,20] mV for the INa
shift intervention; [1,80] for the ICaL conductance scaling; and
[0,1] for the IKr conductance scaling. Interval bisection was set
to terminate when consecutive values were less than 10−4 units
apart. EAD simulations for a single compound can be run in
less than 10 minutes, and many compounds can be run in par-
allel. All the code is available to download from github at
https://github.com/teraspawn/EadPredict.
Algorithm 1 Procedure to find the EAD threshold.
1: Set ion channel conductances in cell model to new values based on
drug block.
2: Run cell model to steady state and then save this state to reset to
later.
3: Set upper and lower limits α, β for intervention value.
4: Repeat
5: Reset cell model to earlier state.
6: Set intervention to (α + β) ÷ 2 (e.g. multiply ICaL conductance by
this factor).
7: Run model for 12 s.
8: Check for early afterdepolarisation (upwards trajectory after initial
depolarisation).
9: Adjust α or β using interval bisection.
10: Until |α − β| < 10−4
Linkage analysis
To visualize whether drugs with similar risk require similar
EAD thresholds, linkage analysis was used to create dendro-
grams of drug similarity based on each of the metrics. The
Euclidean distance between the metric values (e.g. APD90 for
each of the drugs) was used to construct a dendrogram, group-
ing drugs which had similar values. To combine metrics, the
results were shifted such that the control value was zero, and
then scaled to be within [−1,1]. Combinations of metrics such
as all the EAD metrics, the EAD metrics with APD90, and all
the metrics together, were then used to create classification
trees. The optimal leaf ordering was calculated using the R
package “dendextend”, to best sort the leaves in descending
order of risk category (without changing the branching
structure).59
This method allows for the grouping of drugs by similarity
rather than by rigid categories, allowing for new compounds to
be visually ranked by closeness to torsadogenic and non-torsa-
dogenic drugs. The output of the optimal leaf ordering algor-
ithm was evaluated by the sum of the square diﬀerence
between the risk category of each drug in the ranking and an
optimal ordering (2,2,…,2,3,3,…,3,4,4,…etc.):
Ranking error ¼
XN
j¼1
ðoj  ajÞ2; ð2Þ
where o is the optimal ordering of risk category, a is the actual
risk category, and N is the number of drugs in the dataset.
Pro-arrhythmic risk classification
As in Mirams et al.,35 risk categories were based on the
Redfern et al.36 classes (with category 1 and category 2 pooled,
as they represent equivalent levels of risk for diﬀerent drug
classes):
• Category 2: Either Class Ia and III antiarrhythmics, or
drugs that have been withdrawn from market due to TdP.
Paper Toxicology Research
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• Category 3: Drugs with a measurable incidence or numer-
ous reports of TdP in humans.
• Category 4: Drugs with isolated reports of TdP in
humans.
• Category 5: Drugs with no reports of TdP in humans.
We also considered a binary classifiers, where categories 2
and 3 were grouped as torsadogenic and categories 4 and 5
were grouped as non-torsadogenic. Results from this were not
materially diﬀerent, and can be found in the ESI spreadsheet
under “Binary”.†
We used EAD thresholds, APDs, diastolic calcium concen-
tration, and hERG IC50/EFTPCmax to classify compounds into
one of the four TdP risk categories described earlier. We tested
two classification methods: linear discriminant analysis (LDA),
and support vector machines (SVM).
Leave-one-out cross-validation and five-group cross-vali-
dation were used to check the robustness and accuracy of both
the classifiers. We evaluated performance by calculating the
errors in classification (how many risk classes away from the
correct class a drug was classified as), and comparing these
means of absolute error, E:
E ¼ 1
N
XN
j¼1
aj  cj
 ; ð3Þ
where, a is the actual category (i.e. the real risk category for the
drug), c is the category assigned using the classification
method, and N is the number of drugs in the dataset.
In LDA, the metrics in categories are assumed to follow a
Normal distribution, and the points where the inferred distri-
butions overlap are used as the category boundaries.60 In SVM,
a hyperplane is used to separate the data points, and the
optimal hyperplane is found by maximising the distance
between the hyperplane and the closest points to it.61
In leave-one-out cross-validation one drug was removed
from the dataset and the boundaries were re-calculated. The
left-out drug was then placed into a risk category based on
these new boundaries. Five-group cross-validation was also
used: drugs were randomly assigned to five groups, and then
each group was removed from the dataset and the classification
boundaries were re-calculated. The drugs in the removed group
were then classified into a risk category based on these new
boundaries, and accuracy was calculated as above.
Results
EAD thresholds
In general, more torsadogenic drugs caused a decrease in the
threshold of intervention required to provoke an EAD, i.e. they
made the electrophysiology models more vulnerable to EADs.
Full tables of EAD thresholds can be found in the ESI.†
Some examples of EADs induced by the ICaL increase proto-
col are shown in Fig. 3. The low risk drug, nitrendipine,
required a greater increase in ICaL conductance (27.23×) than
the control (24.13×) to induce an EAD. Conversely, the high
risk drug cisapride required a much smaller increase (8.23×) to
induce an EAD. Similarly, models whose ion channel conduc-
tances had been modified to simulate the eﬀects of cisapride
required an INa inactivation curve shift of only 15.45 mV to
produce an EAD, whereas at control a larger shift of 17.41 mV
was required, and the low risk drug diltiazem required a shift
of 17.49 mV, greater than control.
In general, ICaL-provoked EAD thresholds were lower for
drugs which strongly block the INa and hERG channels. ICaL
EAD thresholds were not linear with ICaL drug block, showing
that multi-ion channel eﬀects aﬀected the thresholds. Less IKr
block was required to cause an EAD for strong hERG blockers,
except for verapamil, which is a very strong hERG blocker, but
also strongly blocks ICaL. Thioridazine needed no hERG block
to cause an EAD, despite being a strong ICaL blocker. This is
probably due to thioridazine’s very strong eﬀect on hERG, with
an IC50 value of 0.034 × EFTPCmax.
INa inactivation curve shift thresholds were lower for drugs
which strongly block hERG. Unlike the other EAD metrics,
block of ICaL and INa did not increase the EAD threshold for
the INa inactivation curve shift protocol. For example, verapa-
mil, which is a strong hERG and ICaL blocker, had a low INa
shift EAD threshold.
All three of the EAD metrics consistently had the lowest
thresholds for the following drugs: azimilide, cisapride,
ondansetron, terfenadine, and terodiline. Three drugs (ajma-
line, quinidine, and thioridazine) produced EADs without any
intervention required. With the exception of thioridazine (cat-
egory 3), all of these drugs are in the highest risk category 2.
Fig. 3 Some examples of EADs provoked using the L-type calcium
increase protocol, as described in the methods section. The ﬁrst EAD
caused by the increasing intervention for each drug is highlighted in red.
The less torsadogenic drug (nitrendipine) requires more provocation
than the control to cause an EAD (i.e. its EAD threshold is higher), and
the more torsadogenic drug (cisapride) requires less provocation (i.e. its
EAD threshold is lower).
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A table of EAD thresholds and other metrics can be found
in the ESI.†
Linkage analysis
The dendrogram from the linkage analysis of the hERG IC50/
EFTPCmax metric, APD90, and the combined EAD metrics are
shown in Fig. 4. The optimal leaf ordering algorithm was mod-
erately successful in sorting the drugs in ascending order of
torsadogenic risk. Therefore, a classification scheme based on
the similarity of new compounds to existing compounds of
known torsadogenic risk could be a useful tool. The ranking
error measure for all metrics can be found in the ESI.†
Pro-arrhythmic risk classification
Table 2 shows the mean absolute error, E, in classification for
each of the proarrythymic risk markers and classification
methods. Overall, there was good agreement between the
diﬀerent classification schemes and validation procedures.
Full tables of all results can be found in the ESI.†
The leave-one-out analysis showed that the Support Vector
Machine method of classification was more accurate for the
Grandi Lancaster–Sobie metric, the Grandi APD90 metric, the
O’Hara Cqinward metric, and the hERG IC50/EFTPCmax metric.
For all other metrics, Linear Discriminant Analysis was more
accurate.
Using LDA, the most accurate metrics were the O’Hara ICaL
increase EAD metric and the O’Hara ICaL increase EAD metric
combined with the Grandi APD90 metric. Using SVM, the most
accurate metric was the Grandi Lancaster–Sobie metric, fol-
lowed by Grandi APD90.
The least accurate metric using LDA was the cqInward
metric. Using SVM, the least accurate metric was the IKr EAD
protocol, followed by the INa inactivation curve shift EAD
metric.
The best metric over all classification methods was the
Grandi Lancaster–Sobie metric using SVM, and the worst over
all classification method was the IKr EAD protocol using SVM.
The ICaL increase EAD metric correctly classified cibenzo-
line, desipramine, and fluvoxamine into categories 5, 4, and 4,
respectively, while the APD90 metric mis-classified them into
the more dangerous categories 4, 3, and 3, respectively, and
the hERG IC50/EFTPCmax metric mis-classified all three drugs
into the most dangerous category 2.
Discussion
In this paper, we have presented a novel method for predicting
pro-arrhythmic risk by provoking EADs in computational
models of cardiac cells, in combination with simulated ion
channel block. As expected, EAD thresholds were usually lower
for drugs which strongly block hERG, except when hERG block
was combined with other ion channel block. ICaL block
removed the eﬀect of hERG block on the IKr EAD threshold, for
example, verapamil, a strong ICaL blocker, required a large
decrease in IKr current to cause an EAD despite being a strong
hERG blocker. This indicates that for patients with LQT2 or
Table 2 Mean absolute errors in classiﬁcation, calculated using eqn (3). The “5 LDA” and “5 SVM” rows are the results from the 5-group cross-vali-
dation of linear discriminant analysis classiﬁcation and support vector machines classiﬁcation, respectively. The “1 LDA” and “1 SVM” rows are the
results from leave-one-out cross-validation. The columns are arranged by the lowest sum of errors from the four classiﬁcation measures. Yellow
cells show metrics with low errors and purple cells have high errors. ‘L&S’ refers to the diastolic calcium concentration-APD50 combination metric
from a paper by Lancaster & Sobie,39 ‘cqInward’ refers to the metric from Li et al.48 and ‘Redfern hERG Safety Factor’ refers to the hERG IC50/
EFTPCmax metric proposed in Redfern et al.,
36 as discussed above
Fig. 4 Left: Linkage analysis based on the hERG IC50/EFTPCmax metric.
Centre: Linkage analysis based on the APD90 metric. Right: Linkage ana-
lysis based on the ICaL EAD threshold metric. Risk categories are indi-
cated by colour: category 2 (dangerous) drugs are shown in red, cat-
egory 3 in yellow, category 4 in black, and category 5 (safe) in green.
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other hERG mutations, drugs which block ICaL could be ben-
eficial in preventing TdP. ICaL EAD thresholds were lower for
drugs which strongly block both the INa and hERG channels.
Therefore, for patients with increased ICaL activity, due to ICaL
agonists or genetic mutations, drugs which block both INa and
hERG could increase the risk of TdP. INa inactivation curve
shift thresholds were not increased by ICaL block—for example,
verapamil had a low INa EAD threshold despite strongly block-
ing ICaL. This indicates that, for patients with Brugada syn-
drome, the torsadogenic eﬀects of hERG block cannot be ame-
liorated by ICaL block. ICaL increase as a torsadogenic risk
metric showed clear improvement over the hERG ‘safety
margin’ marker of IC50/EFTPCmax.
In general, results were consistent over classification
methods and evaluation scheme, as shown by leave-one-out
cross-validation and five-group cross-validation.
The ICaL increase EAD metric sorted cibenzoline, desipra-
mine, and fluvoxamine into their correct risk categories, while
both hERG IC50/EFTPCmax and Grandi APD90 classified them
into more dangerous categories. All three of these drugs are
relatively strong ICaL blockers. Cibenzoline is also a strong INa
blocker and a weak IpNa blocker. Block of the persistent
sodium or L-type calcium currents have been shown to sup-
press EADs.62,63 These results show that EAD metrics can accu-
rately predict the torsadogenicity of drugs which block hERG
and increase APD without causing TdP.
Amiodarone was persistently misclassified by every metric
except for hERG IC50/EFTPCmax using LDA, and the IKr EAD
metric and cqInward metric using SVM. Amiodarone weakly
blocks several ion channels, but also has active metabolites
that were not considered here.64 This combination of ion
channel block leads to only a small increase in APD, and
slightly decreased EAD thresholds. Ion channel block by amio-
darone has been shown to be use-dependent, and there is evi-
dence that amiodarone binds only to the open state of the INa
channel. Therefore, a more detailed model of amiodarone
binding kinetics may be required. However, despite being a
Class III antiarrythmic, amiodarone poses a much lower, if
still measurable, TdP risk than most other compounds in risk
category one65 and may therefore be a candidate for re-classifi-
cation into a lower clinical risk category.
Following APD-based metrics, an EAD-based approach to
pro-arrhythmic risk prediction oﬀers a mechanistic link
between ion channel block and TdP.35,37 Building on previous
EAD-based metrics,40,41 our method looks at causes other than
increased drug concentration as a cause of TdP, and incorpor-
ates the action of underlying disease states. Linkage analysis
may allow for more fine-grained risk ranking and be helpful in
showing compounds with similar properties.
The separation of drugs into risk categories based on TdP
clinical incidence is a diﬃcult problem. TdP can only be diag-
nosed when a patient is being monitored on an electrocardio-
gram, so episodes of TdP may be missed, giving underesti-
mates of incidence. In addition, there is little publicly-avail-
able information on drug prescription numbers, meaning that
it is diﬃcult to calculate the number of TdP cases per prescrip-
tion/dose. The lack of information about TdP incidence per
dose makes risk classes uncertain, and a drug prescribed to
people who are more likely to get electrocardiograms will have
an increase in the number of cases of TdP diagnosed for that
drug compared to a similarly torsadogenic drug. Wiśniowska
and Polak44 showed how diﬀerent risk classifications have
been given to the same drugs in diﬀerent studies. Our strategy
of using compounds with uncontroversial risk categorisations
could ameliorate this problem, but the diﬀerences in risk cat-
egory are fundamentally due to a lack of data on incidence.
The approach we have presented suggests a strategy by
which risk assessments might be made for diﬀerent patient
subgroups (analogous to the diﬀerent disease-mimicking EAD
provoking interventions we applied). But as discussed, at
present incidence data for the population as a whole is lacking,
and this problem is exacerbated for smaller patient subgroups,
making evaluation of our patient-group-specific predictions
impossible at present. To improve these and other TdP predic-
tion eﬀorts, more data on TdP incidence rates will be needed.
One weakness of our study is the variety of sources from
which the IC50 values were obtained. The diﬀerences in experi-
mental protocol, temperatures, cell types and equipment used
in these experiments may add uncertainty to our simulations,66
which we have not included in the computations presented
here. A dataset from a single set of manual patch-clamp experi-
ments with low variability would allow standardisation across
pro-arrhythmic risk classification methods for a range of drugs.
There are a large number of available cardiac cell models.
For the afterdepolarization aspects of this study, we have used
only the O’Hara et al.43 model, because it includes the persist-
ent sodium current. The addition of an appropriate late
sodium current to existing models would be a useful extension
to this work, to allow us to look at predictions from a wider
range of models. This is work we are pursuing. We did not use
the new dynamic hERG block model from Li et al. (2017)48
which may explain why our implementation of the Cqinward
metric was not as successful as in that paper.
Our study does not look at pro-arrhythmic markers at the
tissue or whole heart level. EADs are cell-level phenomena
that interact with several other factors in the onset of TdP in
tissue.67 The eﬀects of spatial heterogeneity in ion channel
expression and in fibre organisation on the arrhythmogenic
eﬀects of EAD susceptibility induced by drug block are likely
to be significant in the translation from single-cell EADs to
tissue- and organ-level eﬀects.
Instead of using a simple pore-block model for drug inter-
actions with ion channels, it would be interesting to account for
diﬀerent hERG binding kinetics, which have been explored in a
recent study.48 The diﬀerences in binding may alter the eﬀect of
the drugs on action potential duration and EAD susceptibility.
Conclusions
We have proposed and investigated novel metrics for predict-
ing drug-induced torsadogenic risk based on early-stage pre-
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clinical data on ion channel block. Our EAD-based metrics
combine ion channel block data with disease states in order to
predict increased EAD susceptibility in cell models, as a
marker for pro-arrhythmic risk. Some EAD metrics were an
improvement on the hERG IC50/EFTPCmax safety margin as a
predictor of clinical incidence of Torsades de Pointes. The ICaL
increase metric performed well, and was more accurate than
hERG block alone, but was not as predictive as simpler
measures such as simulated action potential duration we have
published previously. This may be because diﬀerent routes to
EADs mimic diﬀerent diseases in patient subgroups and rep-
resent risk well for these patients only, but evaluating this is
diﬃcult without further data on clinical TdP incidence rates.
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